Evidence map›Paper›PMID 26685324›Full record

ArticleJapanese journal of clinical oncology2016

The chimeric transcript RUNX1-GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer.

Rie Ishikawa, Yosuke Amano, Masanori Kawakami, Mitsuhiro Sunohara, Kousuke Watanabe, Hidenori Kage, Nobuya Ohishi, Yutaka Yatomi, Jun Nakajima, Masashi Fukayama and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Rie IshikawaDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Yosuke AmanoDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Masanori KawakamiDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Mitsuhiro SunoharaDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Kousuke WatanabeDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Hidenori KageDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Nobuya OhishiDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Yutaka YatomiDepartment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo.
Jun NakajimaDepartment of Cardiothoracic Surgery, The University of Tokyo Hospital, Tokyo.
Masashi FukayamaDepartment of Pathology, The University of Tokyo Hospital, Tokyo, Japan.
Takahide NagaseDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo.
Daiya TakaiDepartment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo dtakai-ind@umin.ac.jp.
University of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimera was detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although there was no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1-GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.

Indexed as

AgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungChimeraCore Binding Factor Alpha 2 SubunitFemaleGlutaredoxinsHumansLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPostoperative PeriodPredictive Value of TestsPrognosisBiomarkers, TumorCore Binding Factor Alpha 2 SubunitGLRX5 protein, humanGlutaredoxinsRUNX1 protein, humanbiological markersgene fusionGLRX5non-small-cell lung cancerRUNX1

Identifiers

PMID26685324
PMCPMC4731000
OpenAlexW2306390344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.